This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-12. Anything still debated is marked as such rather than presented as settled.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Working mother advocate and Entrepreneur writer Christine Michel Carter documented her experience pumping in a bathroom while working for an employer violating the Fair Labor Standards Act. In 2022, the Providing Urgent Maternal Protections for Nursing Mothers Act, also known as the PUMP Act, became law in the United States. It mandates that salaried workers who are breastfeeding must have break time and a private space that is not a bathroom. However, employers who do not have 50 or more employees do not have to follow this law if following it would create an undue hardship because of expense or difficulty. In April 2018, the U.S. Senate's rules were changed to allow any senator with a child under one year of age to bring them on the Senate floor and breastfeed them during voting. In Canada, British Columbia and Ontario, provincial Human Rights Codes prevent workplace discrimination due to breastfeeding. In British Columbia, employers are required to provide accommodation to employees who breastfeed or express breast milk. Although no specific requirements are mandated, under the Human Rights Code, accommodations suggested include paid breaks (not including meal breaks), private facilities that include clean running water, comfortable seating areas, and refrigeration equipment, as well as flexibility in terms of work-related conflicts. In Ontario, employers are encouraged to accommodate breastfeeding employees by providing additional breaks without fear of discrimination.
The term matrix-assisted laser desorption ionization (MALDI) was coined in 1985 by Franz Hillenkamp, Michael Karas and their colleagues. These researchers found that the amino acid alanine could be ionized more easily if it was mixed with the amino acid tryptophan and irradiated with a pulsed 266 nm laser. The tryptophan was absorbing the laser energy and helping to ionize the non-absorbing alanine. Peptides up to the 2843 Da peptide melittin could be ionized when mixed with this kind of "matrix". The breakthrough for large molecule laser desorption ionization came in 1987 when Koichi Tanaka of Shimadzu Corporation and his co-workers used what they called the "ultra fine metal plus liquid matrix method" that combined 30 nm cobalt particles in glycerol with a 337 nm nitrogen laser for ionization. Using this laser and matrix combination, Tanaka was able to ionize biomolecules as large as the 34,472 Da protein carboxypeptidase-A. Tanaka received one-quarter of the 2002 Nobel Prize in Chemistry for demonstrating that, with the proper combination of laser wavelength and matrix, a protein can be ionized. Karas and Hillenkamp were subsequently able to ionize the 67 kDa protein albumin using a nicotinic acid matrix and a 266 nm laser. Further improvements were realized through the use of a 355 nm laser and the cinnamic acid derivatives ferulic acid, caffeic acid and sinapinic acid as the matrix.
sanctions from 1981 to 2000, political scientist Dursun Peksen found sanctions to be counterproductive, failing to improve human rights and instead leading to a further decrease in sanctioned countries' "respect for physical integrity rights, including freedom from disappearances, extrajudicial killings, torture, and political imprisonment." Former CIA Deputy Director David Cohen wrote that the logic of coercive sanctions "does not hold, however, when the objective of sanctions is regime change. Put simply, because the cost of relinquishing power will always exceed the benefit of sanctions relief, a targeted state cannot conceivably accede to a demand for regime change." Political scientist Lisa Martin criticized a game theory view of sanctions, arguing that proponents characterize success so broadly—applying it to outcomes from "renegotiation" to "influencing global public opinion"—that the terminology of "winning" and "losing" overextends those concepts.
== Regulatory in the U.S. == The Clinical Laboratory Improvement Amendments (CLIA) regulate any laboratory testing and require laboratories to obtain certificates to do any testing on human specimens for health assessment or to diagnose, prevent, or treat disease. Three federal agencies partner together to cover the responsibilities put forward in the regulations: the Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), and the Centers for Disease Control and Prevention (CDC). In addition, accreditation standards developed by Joint Commission and College of American Pathologists have been developed to improve quality.
Trimethylsilyl (TMS) — Potassium fluoride, acetic acid or potassium carbonate in methanol Triethylsilyl (TES) — 10–100× stabler than a TMS group. Cleaved with trifluoroacetic acid in water/tetrahydrofuran, acetic acid in water/tetrahydrofuran, or hydrogen fluoride in water or pyridine tert-Butyldimethylsilyl (TBDMS or TBS) — Cleaved with acetic acid in tetrahydrofuran/water, Pyridinium tosylate in methanol, trifluoroacetic acid in water, hydrofluoric acid in acetonitrile, pyridinium fluoride in tetrahydrofuran, tetrabutylammonium fluoride in THF. Commonly protects 2'-hydroxy function in oligonucleotide synthesis. Triisopropylsilyl (TIPS) — Similar conditions to TBS but longer reaction times. tert‑Butyldiphenylsilyl (TBDPS) — Similar conditions to TBS but even longer reaction times (100–250× slower than TBS and 5–10× slower than TIPS) Benzyl ethers:
Sources: en.wikipedia.org
=== Template synthesis === The template synthesis method uses a nanoporous membrane template composed of cylindrical pores of uniform diameter to make fibrils (solid nanofiber) and tubules (hollow nanofiber). This method can be used to prepare fibrils and tubules of many types of materials, including metals, semiconductors and electronically conductive polymers. The uniform pores allow for control of the dimensions of the fibers so nanofibers with very small diameters can be produced through this method. However, a drawback of this method is that it cannot make continuous nanofibers one at a time.
=== Primary prevention === Primary prevention aims to reduce the risk factors before a disease or condition occurs. Sun protection is the most effective form of primary prevention of photoaging. The major methods of sun protection are sunscreen products, sun protective clothing, and reducing exposure to the sun, especially during peak sun hours (10 AM-4 PM in the spring and summer seasons). Broad-spectrum sunscreen products provide optimal coverage for protection against UV damage because they protect against both types of UVA rays (UVA1 and UVA2) along with UVB rays. Proper application methods and timing are important factors in proper sunscreen use. This includes using a proper quantity of sunscreen, applying sunscreen prior to sun exposure, and consistent reapplication (especially after exposure to water or sweat).
== Clinical significance == Proline hydroxylation requires ascorbic acid (vitamin C). The most obvious, first effects (gingival and hair problems) of absence of ascorbic acid in humans come from the resulting defect in hydroxylation of proline residues of collagen, with reduced stability of the collagen molecule, causing scurvy. Increased serum and urine levels of hydroxyproline have also been demonstrated in Paget's disease. Mass spectrometry analysis showed decreased amount of hydroxyproline post-translational modifications in non inflamed tissue from ulcerative colitis patients when compared to tissue from donors without the disease.
Osteoporosis is a disease of bone where there is reduced bone mineral density, increasing the likelihood of fractures. Osteoporosis is defined in women by the World Health Organization as a bone mineral density of 2.5 standard deviations below peak bone mass, relative to the age and sex-matched average. This density is measured using dual energy X-ray absorptiometry (DEXA), with the term "established osteoporosis" including the presence of a fragility fracture. Osteoporosis is most common in women after menopause, when it is called "postmenopausal osteoporosis", but may develop in men and premenopausal women in the presence of particular hormonal disorders and other chronic diseases or as a result of smoking and medications, specifically glucocorticoids. Osteoporosis usually has no symptoms until a fracture occurs. For this reason, DEXA scans are often done in people with one or more risk factors, who have developed osteoporosis and are at risk of fracture. One of the most important risk factors for osteoporosis is advanced age. Accumulation of oxidative DNA damage in osteoblastic and osteoclastic cells appears to be a key factor in age-related osteoporosis. Osteoporosis treatment includes advice to stop smoking, decrease alcohol consumption, exercise regularly, and have a healthy diet. Calcium and trace mineral supplements may also be advised, as may Vitamin D. When medication is used, it may include bisphosphonates, Strontium ranelate, and hormone replacement therapy.
Type V collagen is a form of fibrillar collagen associated with classical Ehlers–Danlos syndrome. It is found within the dermal/epidermal junction, placental tissues, as well as in association with tissues containing type I collagen. Type V collagen is a part of the family of collagen proteins consisting of Collagen I – Collagen XXVIII. Collagen proteins are often associated with the strengthening and support of many tissues including skin, bones, muscles, and ligaments. There are some studies that suggest that Type V collagen is responsible for the formation of other collagen fibrils in different tissues within the body. According to studies, Collagen V regulates the heterotypic fiber diameter. Type V Collagen is considered a regulatory fibril forming collagen. Collagen V is associated with the COL5A1 gene which is the gene which provides instructions to produce Collagen V. Type V Collagen, like other collagens, is made up of procollagen molecules. Collagen V molecular isoforms are α1(V)α2(V)α3(V), α1(V)3, and α1(V)2 α2(V). These procollagen molecules are made up of three different α -polypeptide chains. These α -polypeptide chains are α1(V), α2(V), and α3(V). Different combinations of these chains form the Type V collagen Isoforms. Procollagen molecules then form mature collagen with the help of enzymes. After the chains are formed, they arrange into thin fibrils. These collagen fibrils then assort with type I collagen fibrils. Type V collagen is a part of the Extracellular Matrix (ECM). Collagen V is gene expression modulated by TGF-β.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。